Cobra Biologics Granted Approval for Research Tax Credit
News Apr 02, 2014
Cobra Biologics has announced that the French Ministry of Higher Education and Research (MESR) has recognized the contract manufacturer as an approved service provider for its antibody and recombinant protein services for the period 2013 to 2015.
French companies which outsource their research and development (R&D) programmes to Cobra’s centre of excellence for mammalian antibody and recombinant protein production will benefit from the research tax credit (Le Crédit d’Impôt Recherche).
The tax credit scheme from the MESR serves as a powerful incentive for research partnerships; encouraging research and development efforts, enhancing the France’s attractiveness for investment, and supporting the development of organizations within the country regardless of their size or industry.
All French companies incurring research expenses are eligible to receive this tax credit which covers 30% of all R&D expenses up to €100 million, and 5% above this threshold.
Peter Coleman, CEO Cobra Biologics, commented: “CIR is a real benefit to our French customers as it encourages them to invest in innovative drugs that are ultimately the driving force for the medicines of tomorrow.”
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE